164 related articles for article (PubMed ID: 32931606)
1. Impact of hepatitis C virus treatment on the risk of non-hepatic cancers among hepatitis C virus-infected patients in the US.
Wang W; Lo Re V; Guo Y; Xiao H; Brown J; Park H
Aliment Pharmacol Ther; 2020 Nov; 52(10):1592-1602. PubMed ID: 32931606
[TBL] [Abstract][Full Text] [Related]
2. Direct-acting antiviral treatment for hepatitis C virus infection and risk of incident liver cancer: a retrospective cohort study.
Singer AW; Reddy KR; Telep LE; Osinusi AO; Brainard DM; Buti M; Chokkalingam AP
Aliment Pharmacol Ther; 2018 May; 47(9):1278-1287. PubMed ID: 29516535
[TBL] [Abstract][Full Text] [Related]
3. Impact of All-Oral Direct-Acting Antivirals on Clinical and Economic Outcomes in Patients With Chronic Hepatitis C in the United States.
Park H; Wang W; Henry L; Nelson DR
Hepatology; 2019 Mar; 69(3):1032-1045. PubMed ID: 30289989
[TBL] [Abstract][Full Text] [Related]
4. Antiviral regimen complexity index as an independent predictor of sustained virologic response in patients with chronic hepatitis C.
Galán RJ; Cidoncha EC; Martin MF; Rodriguez CC; Almeida CV; Verdugo RM
J Manag Care Pharm; 2013; 19(6):448-53. PubMed ID: 23806058
[TBL] [Abstract][Full Text] [Related]
5. Association between treatment of hepatitis C virus and risk of cardiovascular disease among insured patients with the virus in the United States.
Wang W; Chen C; Re VL; Chang SH; Wilson DL; Park H
Pharmacoepidemiol Drug Saf; 2023 Oct; 32(10):1142-1151. PubMed ID: 37278688
[TBL] [Abstract][Full Text] [Related]
6. Incidence of hospitalization for infection among patients with hepatitis B or C virus infection without cirrhosis in Taiwan: A cohort study.
Lee YC; Wang JL; Dong YH; Chen HC; Wu LC; Chang CH
PLoS Med; 2019 Sep; 16(9):e1002894. PubMed ID: 31518344
[TBL] [Abstract][Full Text] [Related]
7. Cancer in People with and without Hepatitis C Virus Infection: Comparison of Risk Before and After Introduction of Direct-Acting Antivirals.
Lam JO; Hurley LB; Lai JB; Saxena V; Seo S; Chamberland S; Quesenberry CP; Champsi JH; Ready J; Chiao EY; Marcus JL; Silverberg MJ
Cancer Epidemiol Biomarkers Prev; 2021 Dec; 30(12):2188-2196. PubMed ID: 34583968
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study.
Carrat F; Fontaine H; Dorival C; Simony M; Diallo A; Hezode C; De Ledinghen V; Larrey D; Haour G; Bronowicki JP; Zoulim F; Asselah T; Marcellin P; Thabut D; Leroy V; Tran A; Habersetzer F; Samuel D; Guyader D; Chazouilleres O; Mathurin P; Metivier S; Alric L; Riachi G; Gournay J; Abergel A; Cales P; Ganne N; Loustaud-Ratti V; D'Alteroche L; Causse X; Geist C; Minello A; Rosa I; Gelu-Simeon M; Portal I; Raffi F; Bourliere M; Pol S;
Lancet; 2019 Apr; 393(10179):1453-1464. PubMed ID: 30765123
[TBL] [Abstract][Full Text] [Related]
9. Sustained virological response from interferon-based hepatitis C regimens is associated with reduced risk of extrahepatic manifestations.
Rossi C; Jeong D; Wong S; McKee G; Butt ZA; Buxton J; Wong J; Darvishian M; Bartlett S; Samji H; Yu A; Binka M; Alvarez M; Adu PA; Tyndall M; Krajden M; Janjua NZ;
J Hepatol; 2019 Dec; 71(6):1116-1125. PubMed ID: 31433302
[TBL] [Abstract][Full Text] [Related]
10. Chronic hepatitis C virus (HCV) increases the risk of chronic kidney disease (CKD) while effective HCV treatment decreases the incidence of CKD.
Park H; Chen C; Wang W; Henry L; Cook RL; Nelson DR
Hepatology; 2018 Feb; 67(2):492-504. PubMed ID: 28873225
[TBL] [Abstract][Full Text] [Related]
11. Proton pump inhibitors are associated with accelerated development of cirrhosis, hepatic decompensation and hepatocellular carcinoma in noncirrhotic patients with chronic hepatitis C infection: results from ERCHIVES.
Li DK; Yan P; Abou-Samra AB; Chung RT; Butt AA
Aliment Pharmacol Ther; 2018 Jan; 47(2):246-258. PubMed ID: 29105111
[TBL] [Abstract][Full Text] [Related]
12. Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis.
Maan R; van Tilborg M; Deterding K; Ramji A; van der Meer AJ; Wong F; Fung S; Sherman M; Manns MP; Cornberg M; Hansen BE; Wedemeyer H; Janssen HL; de Knegt RJ; Feld JJ
Clin Gastroenterol Hepatol; 2016 Dec; 14(12):1821-1830.e6. PubMed ID: 27404965
[TBL] [Abstract][Full Text] [Related]
13. Uptake of and Factors Associated With Direct-acting Antiviral Therapy Among Patients in the Chronic Hepatitis Cohort Study, 2014 to 2015.
Spradling PR; Xing J; Rupp LB; Moorman AC; Gordon SC; Lu M; Teshale EH; Boscarino JA; Schmidt MA; Daida YG; Holmberg SD;
J Clin Gastroenterol; 2018 Aug; 52(7):641-647. PubMed ID: 28590325
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis C coinfection and extrahepatic cancer incidence among people living with HIV.
Willis SJ; Kim HN; Achenbach CJ; Cachay ER; Christopoulos KA; Crane HM; Franco RA; Hurt CB; Kitahata MM; Moore RD; Silverberg MJ; Tien PC; Westreich D; Marcus JL
HIV Med; 2022 Jul; 23(6):620-628. PubMed ID: 34951105
[TBL] [Abstract][Full Text] [Related]
15. Increased mortality in HIV/HCV-coinfected compared to HCV-monoinfected patients in the DAA era due to non-liver-related death.
Chalouni M; Pol S; Sogni P; Fontaine H; Lacombe K; Marc-Lacombe J; Esterle L; Dorival C; Bourlière M; Bani-Sadr F; de Ledinghen V; Zucman D; Larrey D; Salmon D; Carrat F; Wittkop L;
J Hepatol; 2021 Jan; 74(1):37-47. PubMed ID: 32798585
[TBL] [Abstract][Full Text] [Related]
16. Antiviral Treatment and Response are Associated With Lower Risk of Dementia Among Hepatitis C Virus-Infected Patients.
Tao MH; Gordon SC; Wu T; Trudeau S; Rupp LB; Gonzalez HC; Daida YG; Schmidt MA; Lu M
Am J Geriatr Psychiatry; 2024 May; 32(5):611-621. PubMed ID: 38199936
[TBL] [Abstract][Full Text] [Related]
17. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ
J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis C virus-related complications are increasing in women veterans: A national cohort study.
Kramer JR; El-Serag HB; Taylor TJ; White DL; Asch SM; Frayne SM; Cao Y; Smith DL; Kanwal F
J Viral Hepat; 2017 Nov; 24(11):955-965. PubMed ID: 28815822
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis C Virus (HCV) Treatment With Directly Acting Agents Reduces the Risk of Incident Diabetes: Results From Electronically Retrieved Cohort of HCV Infected Veterans (ERCHIVES).
Butt AA; Yan P; Aslam S; Shaikh OS; Abou-Samra AB
Clin Infect Dis; 2020 Mar; 70(6):1153-1160. PubMed ID: 30977808
[TBL] [Abstract][Full Text] [Related]
20. HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. Veterans with HCV.
Kanwal F; Kramer JR; Ilyas J; Duan Z; El-Serag HB
Hepatology; 2014 Jul; 60(1):98-105. PubMed ID: 24615981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
